In addition, intestine-restricted FXR antagonists may ameliorate obesity-related dysfunction and circumvent the potential adverse outcomes resulting from the inhibition of liver FXR. Here, NR1H4 is linked to obesity due to melanocortin 4 receptor deficiency.